Adverum Biotechnologies, Inc.
Clinical trials sponsored by Adverum Biotechnologies, Inc., explained in plain language.
-
Gene therapy shot could end monthly eye injections for wet AMD
Disease control OngoingThis Phase 3 trial tests a single injection of Ixo-vec gene therapy in 311 people with wet age-related macular degeneration (AMD). The goal is to see if it can maintain or improve vision as well as standard aflibercept injections, but with fewer follow-up treatments. Participants…
Phase: PHASE3 • Sponsor: Adverum Biotechnologies, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Gene therapy for wet AMD: could this mean fewer eye injections?
Disease control OngoingThis study follows 23 people with wet age-related macular degeneration who received a single dose of ADVM-022 gene therapy in an earlier trial. Researchers are checking how safe the treatment is over time and whether it continues to control the disease, potentially reducing the n…
Sponsor: Adverum Biotechnologies, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC